# US 2004/0023981 A1 · Salt forms with tyrosine kinase activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0023981 A1
- Document ID: US20040023981A1
- Status: Published application
- Kind: A1
- Application number: 10/607,114
- Filed: 2003-06-26
- Published: 2004-02-05
- Earliest claimed: 2002-07-24
- Inventors: Yu Ren; Shyam B. Karki; Matthew M. Zhao; Mark T. Bidodeau
- Web page: https://patentgrep.com/patent/US20040023981A1

## CPC

- C07D 417/12: linked by a chain containing hetero atoms as chain links
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to salt forms of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angio-genesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, retinal ischemia, macular edema, inflammatory diseases, and the like in mammals.

## Claims

### Claim 1

A polymorphous form of a hydrochloride salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide.

### Claim 2 (depends on 1)

The polymorphic form of the hydrochloride salt according to claim 1 that is characterized by an X-ray powder diffraction pattern having diffraction angles of: 4.49, 9.08, 11.05, 17.76, 19.50, 21.36, 22.99, 27.69, 33.07 and 34.94.

### Claim 3 (depends on 2)

The polymorphic form of the hydrochloride salt according to claim 2 having multiple diffraction peaks between 2° and 35° 2-theta and a melting endotherm of 273° C. at a rate of 5° C. per minute.

### Claim 4 (depends on 1)

The polymorphic form of the hydrochloride salt according to claim 1 that is characterized by an X-ray diffraction pattern having diffraction angles of: 9.14, 11.13, 15.65, 17.84, 19.60, 21.44, 23.92, 24.46, 25.17, 25.80, 25.98, 28.35 and 29.65.

### Claim 5 (depends on 4)

The polymorphic form of the hydrochloride salt according to claim 4 having multiple diffraction peaks between 2° and 30° 2-theta and a melting endotherm at 264° C. at a rate of 5° C. per minute.

### Claim 6 (depends on 1)

The polymorphic form of the hydrochloride salt according to claim 1 that is characterized by an X-ray powder diffraction pattern having diffraction angles of: 4.13, 8.19, 9.97, 12.27, 15.21, 15.91, 16.56, 19.95, 20.23, 24.88 and 26.56.

### Claim 7 (depends on 6)

The polymorphic form of the hydrochloride salt according to claim 6 having multiple diffraction peaks between 2 and 30° 2-theta and a melting endotherm of 246° C. at a rate of 10° C. per minute.

### Claim 8 (depends on 1)

The polymorphic form of the hydrochloride salt according to claim 1 that is characterized by an X-ray powder diffraction pattern having diffraction angles of: 10.17, 12.74, 15.01, 15.35, 16.09, 17.29, 17.89, 18.42, 18.88, 19.04, 20.00, 20.45, 21.49, 22.78, 24.44, 25.33, 26.04, 28.86, 30.31 and 31.00.

### Claim 9 (depends on 8)

The polymorphic form of the hydrochloride salt according to claim 8 having multiple diffraction peaks between 2° and 35° 2-theta and a melting endotherm of 265° C. at a rate of 5° C. per minute.

### Claim 10

A hydrochloride ethanolate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide characterized by an X-ray powder diffraction pattern having diffraction angles of: 6.09, 10.96, 12.03, 16.52, 16.79, 17.99, 18.31, 18.41, 19.87, 20.01, 21.42, 21.63, 24.82, 25.04, 25.44, 25.81, 27.16, 29.92, 34.89, and 36.43.

### Claim 11 (depends on 10)

The hydrochloride ethanolate salt according to claim 10 having multiple diffraction peaks between 2° and 40° 2-theta and a melting endotherm of 268° C. at a rate of 5° C. per minute.

### Claim 12

A tartrate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide characterized by an X-ray powder diffraction pattern having diffraction angles of: 10.22, 11.14, 13.44, 14.28, 16.76, 22.86, 24.98, 25.94, 28.72, and 29.86.

### Claim 13 (depends on 12)

The tartrate salt according to claim 12 having multiple diffraction peaks between 2° and 30° 2-theta and a melting endotherm of 150° C. at a rate of 10° C. per minute.

### Claim 14

A polymorphous form of a citrate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide.

### Claim 15 (depends on 14)

The polymorphic form of the citrate salt according to claim 14 that is characterized by an X-ray powder diffraction pattern having multiple diffraction peaks between 2° and 30° 2-theta and a melting endotherm of 153° C. at a rate of 10° C. per minute.

### Claim 16 (depends on 14)

The polymorphic form of the citrate salt according to claim 14 that is characterized by an X-ray powder diffraction pattern having diffraction angles of: 2.04, 4.16, 16.21, 16.31, 16.94, 17.72, 18.66, 19.61, 20.34, 20.97, 21.28, 21.46, 22.94,23.98, 27.10, 27.85, 28.30.

### Claim 17 (depends on 16)

The polymorphic form of the citrate salt according to claim 16 having multiple diffraction peaks between 2° and 30° 2-theta and a melting endotherm of 164° C. at a rate of 5° C. per minute.

### Claim 18 (depends on 14)

The polymorphic form of the citrate salt according to claim 14 characterized by an X-ray powder diffraction pattern having diffraction angles of: 4.51, 14.07, 15.09, 15.55, 15.82, 17.02, 17.70, 18.60, 20.70, 22.42, 23.71, 24.52, 25.40, 26.13, 27.91, 28.46, 28.58.

### Claim 19

A polymorphous form of a besylate salt of of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide.

### Claim 20 (depends on 19)

The polymorphic form of the besylate salt according to claim 19 that is characterized by an X-ray powder diffraction pattern having diffraction angles of: 9.54, 9.80, 12.90, 15.99, 18.54, 20.82, 21.16, 24.51.

### Claim 21 (depends on 20)

The polymorphic form of the besylate salt according to claim 20 having multiple diffraction peaks between 2° and 25° 2-theta and a melting endotherm of 234° C. at a rate of 5° C. per minute.

### Claim 22 (depends on 19)

The polymorphic form of the besylate salt according to claim 19 that is characterized by an X-ray powder diffraction pattern having diffraction angles of: 8.66, 15.88, 16.27, 18.05, 18.43, 20.73, 22.94, 23.06, 23.64, 23.92, 24.34, 24.51.

### Claim 23 (depends on 22)

The polymorphic form of the besylate salt according to claim 22 having multiple diffraction peaks between 2° and 25° 2-theta and a melting endotherm of 232° C. at a rate of 5° C. per minute.

### Claim 24 (depends on 1)

A pharmaceutical composition that is comprised of a polymorphous form of the hydrochloride salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in accordance with claim 1 and a pharmaceutically acceptable carrier.

### Claim 25 (depends on 10)

A pharmaceutical composition that is comprised of the hydrochloride ethanolate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in accordance with claim 10 and a pharmaceutically acceptable carrier.

### Claim 26 (depends on 12)

A pharmaceutical composition that is comprised of the tartrate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in accordance with claim 12 and a pharmaceutically acceptable carrier.

### Claim 27 (depends on 14)

A pharmaceutical composition that is comprised of a polymorphous form of the citrate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in accordance with claim 14 and a pharmaceutically acceptable carrier.

### Claim 28 (depends on 19)

A pharmaceutical composition that is comprised of a polymorphous form of the besylate salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in accordance with claim 19 and a pharmaceutically acceptable carrier.

### Claim 29 (depends on 1)

A method of treating or preventing cancer in a mammal in need of such treatment which is comprised of administering to said mammal a therapeutically effective amount of the crystalline form of the hydrochloride salt of 4-[2-(5-cyano-thiazol-2-ylamino)-pyridin-4-ylmethyl]-piperazine-1-carboxylic acid methylamide in accordance with claim 1.

### Claim 30 (depends on 29)

A method of treating cancer or preventing cancer in accordance with claim 29 wherein the cancer is selected from cancers of the brain, genitourinary tract, lymphatic system, stomach, larynx and lung.

### Claim 31 (depends on 29)

A method of treating or preventing cancer in accordance with claim 29 wherein the cancer is selected from histiocytic lymphoma, lung adenocarcinoma, small cell lung cancers, pancreatic cancer, glioblastomas and breast carcinoma.

### Claim 32 (depends on 1)

A method of treating or preventing a disease in which angiogenesis is implicated, which is comprised of administering to a mammal in need of such treatment a therapeutically effective amount of the polymorphic form of the hydrochloride salt of claim 1.

### Claim 33 (depends on 32)

The method in accordance with claim 32 wherein the disease is an ocular disease.

### Claim 34 (depends on 33)

The method according to claim 33, wherein the ocular disease is retinal vascularization, diabetic retinopathy, age-related macular degeneration, retinal ischema or macular edema.

### Claim 35 (depends on 1)

A method of treating or preventing inflammatory diseases which comprises administering to a mammal in need of such treatment a therapeutically effective amount of the polymorphic form of the hydrochloride salt of claim 1.

### Claim 36 (depends on 35)

A method according to claim 35 wherein the inflammatory disease is selected from rheumatoid arthritis, psoriasis, contact dermatitis and delayed hypersensitivity reactions.

### Claim 37 (depends on 1)

A method of treating or preventing a tyrosine kinase-dependent disease or condition which comprises administering a therapeutically effective amount of the polymorphic form of the hydrochloride salt of claim 1.

### Claim 38 (depends on 1)

A method of treating or preventing bone associated pathologies selected from osteosarcoma, osteoarthritis, and rickets which comprises administering a therapeutically effective amount of the polymorphic form of the hydrochloride salt of claim 1.

### Claim 39 (depends on 24)

The composition of claim 24 further comprising a second compound selected from:
1) an estrogen receptor modulator,
2) an androgen receptor modulator,
3) retinoid receptor modulator,
4) a cytotoxic agent,
5) an antiproliferative agent,
6) a prenyl-protein transferase inhibitor,
7) an HMG-CoA reductase inhibitor,
8) an HIV protease inhibitor,
9) a reverse transcriptase inhibitor, and
10) another angiogenesis inhibitor.

### Claim 40 (depends on 39)

The composition of claim 39, wherein the second compound is another angiogenesis inhibitor selected from the group consisting of a tyrosine kinase inhibitor, an inhibitor of epidermal-derived growth factor, an inhibitor of fibroblast-derived growth factor, an inhibitor of platelet derived growth factor, an MMP inhibitor, an integrin blocker, interferon-α, interleukin-12, pentosan polysulfate, a cyclooxygenase inhibitor, carboxyamidotriazole, combretastatin A-4, squalamine, 6-O-chloroacetyl-carbonyl)-fumagillol, thalidomide, angiostatin, troponin-1, and an antibody to VEGF.

### Claim 41 (depends on 39)

The composition of claim 39, wherein the second compound is an estrogen receptor modulator selected from tamoxifen and raloxifene.

### Claim 42 (depends on 1)

A method of treating cancer which comprises administering a therapeutically effective amount of the polymorphic form of the hydrochloride salt of claim 1 in combination with radiation therapy.

### Claim 43 (depends on 1)

A method of treating or preventing cancer which comprises administering a therapeutically effective amount of the polymorphic form of the hydrochloride salt of claim 1 in combination with a compound selected from:
1) an estrogen receptor modulator,
2) an androgen receptor modulator,
3) retinoid receptor modulator,
4) a cytotoxic agent,
5) an antiproliferative agent,
6) a prenyl-protein transferase inhibitor,
7) an HMG-CoA reductase inhibitor,
8) an HIV protease inhibitor,
9) a reverse transcriptase inhibitor, and
10) another angiogenesis inhibitor.

### Claim 44 (depends on 1)

A method of treating cancer which comprises administering a therapeutically effective amount of the polymorphic form of the hydrochloride salt of claim 1 bin combination with radiation therapy and a compound selected from:
1) an estrogen receptor modulator,
2) an androgen receptor modulator,
3) retinoid receptor modulator,
4) a cytotoxic agent,
5) an antiproliferative agent,
6) a prenyl-protein transferase inhibitor,
7) an HMG-CoA reductase inhibitor,
8) an HIV protease inhibitor,
9) a reverse transcriptase inhibitor, and
10) another angiogenesis inhibitor.

### Claim 45 (depends on 1)

A method of treating or preventing cancer which comprises administering a therapeutically effective amount of the polymorphic form of the hydrochloride salt of claim 1 and paclitaxel or trastuzumab.

### Claim 46 (depends on 1)

A method of treating or preventing cancer which comprises administering a therapeutically effective amount of the polymorphic form of the hydrochloride salt of claim 1 and a GPIIb/IIIa antagonist.

### Claim 47 (depends on 61)

The method of claim 61 wherein the GPIIb/IIIa antagonist is tirofiban.

### Claim 48 (depends on 1)

A method of reducing or preventing tissue damage following a cerebral ischemic event which comprises administering a therapeutically effective amount of the polymorphic form of the hydrochloride salt of claim 1.

### Claim 49 (depends on 1)

A method of treating or preventing cancer which comprises administering a therapeutically effective amount of polymorphic form of the hydrochloride salt of claim 1 in combination with a COX-2 inhibitor.

### Claim 50 (depends on 1)

A method of treating or preventing preeclampsia which comprises administering a therapeutically effective amount of the polymorphic form of the hydrochloride salt of claim 1.

### Claim 51 (depends on 1)

A method of treating or preventing tissue damage due to bacterial meningitis which comprises administering a therapeutically effective amount of the polymorphic form of the hydrochloride salt of claim 1.

### Claim 52 (depends on 1)

A method to treat or prevent endometrioses which comprises administering a therapeutically effective amount of the polymorphic form of the hydrochloride salt of claim 1.

### Claim 53 (depends on 1)

A method of treating or preventing diabetic retinopathy which comprises administering a therapeutically effective amount of the polymorphic form of the hydrochloride salt of claim 1 in combination with a PPAR-γ agonist.
